[Asia Economy Reporter Yoo Hyun-seok] Jeil Pharmaceutical is showing strong performance. The news that Nafamostat is also effective for patients with the novel coronavirus infection (COVID-19) appears to have had an impact.
As of 10:20 AM on the 4th, Jeil Pharmaceutical was trading at 58,900 KRW, up 6.90% (3,800 KRW).
On the same day, a media outlet reported that Professors Lee Ji-young and Jang Seok-bin from the Department of Infectious Diseases at Dankook University Hospital conducted clinical treatment using Nafamostat on three confirmed COVID-19 patients, all of whom were fully cured without side effects.
Dankook University Hospital is known to be one of the 10 hospitals approved by the Ministry of Food and Drug Safety for clinical treatment based on research results from the Korea Pasteur Institute.
Jeil Pharmaceutical holds a generic license for Nafamostat developed by the Japanese pharmaceutical company Torii and sells treatments such as acute pancreatitis medication.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
